| Literature DB >> 34205154 |
Ying Wang1, Junlong Li1, Ning Li1.
Abstract
The genus Curculigo, as a folk herbal medicine, has been used for many years in China, treating impotence, limb limpness, and arthritis of the lumbar and knee joints. The last systematic review of the genus Curculigo was written in 2013, scientifically categorizing the phytochemistry and biological activities. Hitherto, the original compounds and their pharmacological activities were presented as the development of this genus, but there is not an updated review. To conclude the progression of the genus Curculigo, we collected the new literature published from 2013 to 2021 in PubMed, Web of Science, Google Scholar databases, and the Chinese National Knowledge Infrastructure. The novel chlorophenolic glucosides, curculigine, phenolic glycosides, orcinosides and polysaccharides were isolated from Curculigo. The new analyzing methods were established to control the quality of Curculigo as a herbal medicine. In addition, the pharmacological effects of Curculigo focused on anti-diabetes, antibacterial, anti-inflammatory, osteoporosis, antioxidation, etc. The antitumor and neuroprotective activities were newly explored in recent years. The application of herbal medicine was gradually developed in scientific methods. The medicinal value of the genus Curculigo needs to further investigate its pharmacological mechanisms. This new review offers more insights into the exploitation of the pharmacological value of the genus Curculigo.Entities:
Keywords: genus Curculigo; herbal medicine; pharmacological activities; phytochemistry
Mesh:
Substances:
Year: 2021 PMID: 34205154 PMCID: PMC8199960 DOI: 10.3390/molecules26113396
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Predicted chemical structures of polysaccharides and monosaccharide (1–3) from the plants of the genus Curculigo.
Figure 2Norlignans (4–7) from the plants of genus Curculigo.
Scheme 1Proposed hypothetical biosynthetic pathway for capitulactones A–C (4–6).
Scheme 2Total synthesis pathway for Sinenside A (7).
Figure 3Chlorophenolic glucosides (8–28) from the plants of the genus Curculigo.
Figure 4Phenolic compounds (29–51) from the plants of the genus Curculigo.
Figure 5Terpenoids (52–58) from the plants of the genus Curculigo.
Figure 6Cyclic peptides (59–66) from the plants of the genus Curculigo.
Pharmacological effects of the genus Curculigo.
| Pharmacological Activity | Tested Substance | Species | In Vivo/In Vitro | Model | Administration (In Vivo) | Dose/Concentration | Toxicology | References |
|---|---|---|---|---|---|---|---|---|
| Anti-diabetic Activity | hydroalcoholic extract |
| in vivo | STZ-nicotinamide induced diabetic nephropathy | oral administration | 600 mg/kg | - | [ |
| ethanol extract |
| in vivo | STZ-nicotinamide induced diabetic nephropathy | oral administration | 600 mg/kg | - | [ | |
| supplemented diet |
| in vitro | STZ-induced diabetic rats | oral administration | 5 and 10% | nephrotoxicity | [ | |
| corn steep liquor extract |
| in vitro | STZ-induced diabetic rats | oral administration | 300 mg/kg of the extract(s) for 28 days | - | [ | |
| corn steep liquor extract |
| in vitro | STZ-induced diabetic rats | oral administration | 300 mg/kg of the extract(s) for 28 days | LD50 = 2828 mg/kg | [ | |
| aqueous extract |
| in vivo | HFD+STZ-induced diabetic rats | oral administration | 5 g/d | non-toxic | [ | |
| ethanol extract |
| in vitro | 3T3-L1 | - | 10 and 100 μg/mL | - | [ | |
| Anti-osteoporosis | curculigoside |
| in vitro | osteoblasts | - | 25–100 μg/mL | - | [ |
| curculigoside |
| in vitro | HAFSCs | - | 1–100 mg/mL | 200 mg/mL inhibit cell growth | [ | |
| curculigoside |
| in vitro | MC3T3-E1 | - | 10 μM | - | [ | |
| curculigoside |
| in vivo | iron-overload mice model | oral administration | 100 mg/kg | - | [ | |
| COP90-1 |
| in vitro | primary mouse osteoblasts | - | 21.7 μM | - | [ | |
| COP70-3 |
| in vitro | primary rat osteoblasts | - | - | non-toxic | [ | |
| curculigine E-H |
| in vitro | MC3T3-E1 | - | 10 μM | - | [ | |
| curculigine M, N, O |
| in vitro | MC3T3-E1 | - | - | - | [ | |
| curculigine K, L |
| in vitro | MC3T3-E1 | - | - | - | [ | |
| curculigoside |
| in vivo | BMSCs | 100 μM | 1000 μM decreased cell viability | [ | ||
| curculigoside |
| in vivo | transgenic mice | oral administration | - | - | [ | |
| Antioxidant | corn steep liquor extract, n-butanol and methanol solvent fractions |
| in vivo | STZ diabetic rats | oral administration | 300 mg/kg | - | [ |
| ethanol extract |
| in vitro | cisplatin-induced HEI-OC1 cell damage | - | 1–25 μg/mL | 50 μg/mL decreased cell viability | [ | |
| methanol extract |
| in vivo | cyclophosphamide-induced | oral administration | 25 mg/kg | non-toxic | [ | |
| decoctions (DECs) and hydro-alcoholic extracts |
| in vitro | CCRF-CEM and | - | 43.57 ± 4.21 mg/mL and 290.96 ± 2.31 mg/mL | non-toxic | [ | |
| hydro-alcoholic extract |
| in vitro | - | oral administration | 100 mg/kg | - | [ | |
| ethylacetate fraction, aqueous ethylacetate |
| in vivo | - | oral administration | 52 ± 0.66 μg/mL | - | [ | |
| aqueous extract |
| in vitro | rat penile homogenate | - | 0.95 mg/mL | [ | ||
|
|
| in vivo | received the high-fat diet | oral administration | 0.3 mL/kg | - | [ | |
| Neuroprotective effect | orcinol glucoside |
| in vivo | CUMS-induced depressive rats | - | 1.5, 3, 6 mg/kg | - | [ |
| crassifoside H |
| in vivo | CUMS-induced depressive rats | oral administration | 2, 4, or 8 mg/kg | - | [ | |
| curculigoside |
| in vivo | SD rats | oral administration | 24, 48, 72 mg/kg, qd | - | [ | |
| methanol extract |
| in vivo | Cyclophosphamide-Induced Neurotoxicity in Murine Model | i.p. | 200 mg/kg, 400 mg/kg | - | [ | |
| curculigoside |
| in vivo | mice | oral administration | 10, 20, 40 mg/kg | - | [ | |
| curculigoside |
| in vivo | mice | intraperitoneal injection | 5 mg/kg | - | [ | |
| curculigoside A |
| in vitro | human brain microvascular endothelial cell line | - | 1–24 μM | - | [ | |
| curculigoside A |
| in vivo | middle cerebral artery occluded (MCAO) model rats | tail vein injection | 10 mg/kg | - | [ | |
| curculigoside |
| in vitro | N-methyl-D-aspartate (NMDA)-induced neuronal cell | - | 1 and 10 μM | - | [ | |
| crassifoside H |
| in vivo | chronic unpredictable mild stress (CUMS)-induced rats | oral administration | 2, 4, and 8 mg/kg d−1 | - | [ | |
| Antitumor | polysaccharides |
| in vivo | mice injected with Hela cells | injected into the lower abdominal region | 20, 40 mg/kg | - | [ |
| polysaccharides |
| in vitro | Hela cells | - | 10, 20, 40, 80 mg/mL | - | [ | |
| CoBAgNPs |
| in vitro | human breast | - | 18.86, 42.43 μg/mL | - | [ | |
| the ethyl acetate extract |
| in vitro | MCRF-7 cells | - | 80 μg/mL | - | [ | |
| curculigoside |
| in vivo | C57BL/6 mice | - | 5 mg/kg | non-toxic | [ | |
| orcinolglucoside nano- lipid carrier (NLC) |
| in vitro | gastrointestinal tract | - | - | - | [ | |
| Antibacteria | the ethanol extract |
| in vitro |
| - | 49 μg/mL | - | [ |
| Coble-AgNPs |
| in vitro | - | 50 μL | 6.33 μg/mL inhibit cell growth | [ | ||
| the constituents of ethanol crude |
| in vitro | - | 100 mg/mL | - | [ | ||
| methanol extract |
| in vitro | Bacillus cereus, Salmonella typhi, Escherichia coli, | - | - | LD50 was found to be greater than 4000 mg/kg | [ | |
| a newly isolated streptomyces sp. 5–10 |
| in vitro | FocTR4 | - | 250 μg/mL, 500 μg/mL | - | [ | |
| Anti-inflammation and Anti-arthritis | curculigoside |
| in vivo | type II collagen induced rat arthritis model | oral administration | 50 mg/kg | - | [ |
| curculigoside |
| in vitro | MH7A cells | - | 4, 8 and 16 μg/mL | - | [ | |
| curculigoside A |
| in vivo | CFA-induced rat arthritis model | oral administration | 10, 20 mg/kg | - | [ | |
| Anti-diarrhea and anti-nociception | methanol extract |
| in vivo | mice | oral administration | 200, 400 mg/kg | lower toxicity | [ |
| Effect on perimenopausal syndrome | total glucosides |
| in vivo | the castrated mice | oral administration | 400 mg/kg | - | [ |
| total glucosides |
| in vivo | Perimenopausal mdel mice | oral administration | 400, 200, 100 mg/kg | - | [ | |
| Male reproductive improvement | BlamusTM |
| in vitro | - | - | - | [ | |
| Cardio-protection | curculigoside |
| in vitro | H9c2 cells | - | 10, 15 μM | - | [ |
| curculigoside |
| in vivo | rat | intravenous injection | 10, 15 mg/kg | - | ||
| Other activities | curculigoside A |
| in vivo | Sprague-Dawley rats | oral administration | 10 or 20 mg/kg | - | [ |